So far this year, Pfizer's (NYSE: PFE) shares have made noticeable progress in emerging from their post-pandemic slump. Year to date, the stock is up 20%, and this is all while the company has remained one of the high-yield dividend stocks, with around a 5.8% forward dividend yield. While the comeback is underway (shares recently hitting a new 52-week high), it remains in its early stages. Pfizer is succeeding in efforts like cost-cutting; the next step is to secure final approval for a new batch of branded pharmaceutical products to counter the looming loss of patent exclusivity on several of its flagship blockbuster drugs. Image source: Getty Images.
CryptoAlerta — análise de criptomoedas e mercado em tempo real